GenoSafe is a French analytical CRO specialized in advanced therapy medicinal products, with recognized expertise in gene and cell therapies. The company provides analytical development, validation, ...

Gate Bioscience, a biotechnology company developing a new class of small molecule medicines aiming to eliminate disease-causing proteins at their source, today announced the close of a $65 million ...

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that the U.S.

A live webcast of the presentation will be available on the Events and Presentations page of CytomX’s website at www.cytomx.com. In addition, management will be available for one-on-one meetings with ...

In Q3 2025, the Company expanded its line of inhalers in the domestic market to include minor cannabinoids, and launched metered dose inhalers in Australia. The company has plans to launch inhalers in ...

Pure Harvest Corporate Group, Inc. (OTC: PHCG) (“PHCG” or the “Company”) today announced it has closed on its acquisition of Mixie IP Holdings, LLC and Mixie Labs, LLC (collectively, “Mixie”). The ...

“Two-Year Outcomes in Female Patients from A Prospective Randomized Trial of Humacyte’s Acellular Tissue Engineered Vessel vs. Autologous Arteriovenous Fistula for Hemodialysis,” to be presented by ...

Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) currently in clinical development. Immunomodulation by intranasal foralumab represents a novel avenue for the treatment of ...

Live demonstrations of Nanox.ARC X to be featured at RSNA booth (3914, South Hall Level 3) every 30 minutes; Innovation Theater presentation to highlight development of pulmonary ...

The Matisse sponsored single-blind, randomized, placebo-controlled study has been executed and managed by Charité Research Organisation located in Berlin, Germany.

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the publication of interim results from its CAMPAIGN trial, a randomized controlled trial (“RCT”) designed to evaluate the ...

Presented new subgroup analyses from phase 3 clinical trial of CAN-2409 in localized prostate cancer at the American Society for Radiation Oncology (ASTRO) 2025 meeting, demonstrating improved ...